Details of the Drug

General Information of Drug (ID: DM45MR0)

Drug Name
HIP-2B
Indication
Disease Entry ICD 11 Status REF
Type-1/2 diabetes 5A10-5A11 Phase 1 [1]
Type-2 diabetes 5A11 Phase 1 [2]
Cross-matching ID
TTD ID
D0ZF8F
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Regenerating human pro-islet peptide (REG3A) TTL4H8N REG3A_HUMAN Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Type-1/2 diabetes
ICD Disease Classification 5A10-5A11
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Regenerating human pro-islet peptide (REG3A) DTT REG3A 1.68E-02 -0.13 -0.87
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01933256) Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells. Am J Pathol.1999 Nov;155(5):1525-33.